Pfizer Inc - Company Profile
Powered by
All the data and insights you need on Pfizer Inc in one report.
- Save hours of research time and resources with
our up-to-date Pfizer Inc Strategy Report
- Understand Pfizer Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View morePfizer Catalyst Calendar
Proactively evaluate Pfizer Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Pfizer Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
15 Aug 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
15 Aug 2019 | Constraining Patent Expiry (US) | Pfizer Inc | PFE | temsirolimus | Central Nervous System; Immunology; Oncology | Anaplastic Thyroid Cancer; B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia); Bladder Cancer; CNS Lymphoma; Follicular Lymphoma; Follicular Thyroid Cancer; Glioblastoma Multiforme (GBM); Hepatocellular Carcinoma; Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Lymphoblastic Lymphoma; Malignant Glioma; Mantle Cell Lymphoma; Medullary Thyroid Cancer; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Myelodysplastic Syndrome; Ovarian Cancer; Papillary Thyroid Cancer; Peripheral T-Cell Lymphomas (PTCL); Relapsing Remitting Multiple Sclerosis (RRMS); Renal Cell Carcinoma; Rheumatoid Arthritis; Secondary Progressive Multiple Sclerosis (SPMS); T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia); Triple-Negative Breast Cancer (TNBC) | GD Estimates |
15 Aug 2019 | Phase III Trial Initiation | International Breast Cancer Study Group; Pfizer Inc | PFE | palbociclib | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) | Clinical Trial Registry |
13 Aug 2019 | Phase I Trial Initiation | Pfizer Inc | PFE | ervogastat | Gastrointestinal | Non Alcoholic Fatty Liver Disease (NAFLD); Non-Alcoholic Steatohepatitis (NASH) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer